Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05546866
What this trial is testing

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 51
Large-scale testing (Phase 3)Study completedNCT01342965
What this trial is testing

Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 217
Testing effectiveness (Phase 2)UnknownNCT03062800
What this trial is testing

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Who this might be right for
Advanced Nsclc
Qilu Hospital of Shandong University 232
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Large-scale testing (Phase 3)Looking for participantsNCT04853342
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Carcinoma
Allist Pharmaceuticals, Inc. 318
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Testing effectiveness (Phase 2)UnknownNCT04643847
What this trial is testing

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Who this might be right for
EGFR Positive Non-small Cell Lung CancerBrain Metastases
First People's Hospital of Hangzhou 47
Testing effectiveness (Phase 2)Study completedNCT02444819
What this trial is testing

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 33
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Large-scale testing (Phase 3)WithdrawnNCT06093503
What this trial is testing

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie
Early research (Phase 1)Looking for participantsNCT07315113
What this trial is testing

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc. 18
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Testing effectiveness (Phase 2)Looking for participantsNCT06951464
What this trial is testing

BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan University 40
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Large-scale testing (Phase 3)Study completedNCT02044380
What this trial is testing

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 14
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Large-scale testing (Phase 3)Active Not RecruitingNCT04538664
What this trial is testing

Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 308
Testing effectiveness (Phase 2)Looking for participantsNCT04335292
What this trial is testing

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Who this might be right for
Non-Small Cell Lung Cancer
Mark Vincent 200
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Next Page